Previous close | 152.40 |
Open | 151.15 |
Bid | 148.60 x 0 |
Ask | 152.00 x 0 |
Day's range | 149.60 - 152.90 |
52-week range | 20.40 - 184.08 |
Volume | |
Avg. volume | 118,800 |
Market cap | 69.523B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | 21.23 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.20 (1.48%) |
Ex-dividend date | 02 May 2023 |
1y target est | N/A |
Investing.com -- Shares in Merck KGaA (ETR:MRCG) slumped by more than 10% on Tuesday after the drugmaker announced that it had discontinued a Phase III study evaluating its treatment for patients with head and neck cancer.
Most readers would already know that Merck KGaA's (ETR:MRK) stock increased by 4.5% over the past three months. Given...
Merck KGaA (MKGAF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.